NI
BMY icon

NDVR Inc’s Bristol-Myers Squibb BMY Stock Holding History

NDVR Inc’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$251K Buy
+4,645
New +$223K 0.21% 81

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

NDVR Inc's BMY Position: Q4 2025 in Review

NDVR Inc opened a new position in Bristol-Myers Squibb (BMY) in Q4 2025: 4,645 shares worth $251K. The stake represents 0.21% of the portfolio and ranks #81 among its holdings.

2,447 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

  • NDVR Inc held 4,645 shares of Bristol-Myers Squibb worth $251K as of Q4 2025.
  • Bristol-Myers Squibb was a new NDVR Inc position in Q4 2025.
  • Bristol-Myers Squibb made up 0.21% of NDVR Inc's portfolio in Q4 2025, its #81 holding.
  • 2,447 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on NDVR Inc's 13F filing for Q4 2025, filed 12 Feb 2026.